Frontiers in Neurology (May 2023)

An online survival predictor in glioma patients using machine learning based on WHO CNS5 data

  • Liguo Ye,
  • Lingui Gu,
  • Zhiyao Zheng,
  • Zhiyao Zheng,
  • Zhiyao Zheng,
  • Xin Zhang,
  • Hao Xing,
  • Xiaopeng Guo,
  • Xiaopeng Guo,
  • Wenlin Chen,
  • Yaning Wang,
  • Yuekun Wang,
  • Tingyu Liang,
  • Hai Wang,
  • Yilin Li,
  • Yilin Li,
  • Shanmu Jin,
  • Shanmu Jin,
  • Yixin Shi,
  • Yixin Shi,
  • Delin Liu,
  • Delin Liu,
  • Tianrui Yang,
  • Tianrui Yang,
  • Qianshu Liu,
  • Qianshu Liu,
  • Congcong Deng,
  • Yu Wang,
  • Yu Wang,
  • Wenbin Ma,
  • Wenbin Ma

DOI
https://doi.org/10.3389/fneur.2023.1179761
Journal volume & issue
Vol. 14

Abstract

Read online

BackgroundThe World Health Organization (WHO) CNS5 classification system highlights the significance of molecular biomarkers in providing meaningful prognostic and therapeutic information for gliomas. However, predicting individual patient survival remains challenging due to the lack of integrated quantitative assessment tools. In this study, we aimed to design a WHO CNS5-related risk signature to predict the overall survival (OS) rate of glioma patients using machine learning algorithms.MethodsWe extracted data from patients who underwent an operation for histopathologically confirmed glioma from our hospital database (2011–2022) and split them into a training and hold-out test set in a 7/3 ratio. We used biological markers related to WHO CNS5, clinical data (age, sex, and WHO grade), and prognosis follow-up information to identify prognostic factors and construct a predictive dynamic nomograph to predict the survival rate of glioma patients using 4 kinds machine learning algorithms (RF, SVM, XGB, and GLM).ResultsA total of 198 patients with complete WHO5 molecular data and follow-up information were included in the study. The median OS time of all patients was 29.77 [95% confidence interval (CI): 21.19–38.34] months. Age, FGFR2, IDH1, CDK4, CDK6, KIT, and CDKN2A were considered vital indicators related to the prognosis and OS time of glioma. To better predict the prognosis of glioma patients, we constructed a WHO5-related risk signature and nomogram. The AUC values of the ROC curves of the nomogram for predicting the 1, 3, and 5-year OS were 0.849, 0.835, and 0.821 in training set, and, 0.844, 0.943, and 0.959 in validation set. The calibration plot confirmed the reliability of the nomogram, and the c-index was 0.742 in training set and 0.775 in validation set. Additionally, our nomogram showed a superior net benefit across a broader scale of threshold probabilities in decision curve analysis. Therefore, we selected it as the backend for the online survival prediction tool (Glioma Survival Calculator, https://who5pumch.shinyapps.io/DynNomapp/), which can calculate the survival probability for a specific time of the patients.ConclusionAn online prognosis predictor based on WHO5-related biomarkers was constructed. This therapeutically promising tool may increase the precision of forecast therapy outcomes and assess prognosis.

Keywords